Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 03 2021
Historique:
received: 10 07 2020
accepted: 23 02 2021
entrez: 19 3 2021
pubmed: 20 3 2021
medline: 21 10 2021
Statut: epublish

Résumé

According to the degree of upper and lower motor neuron degeneration, motor neuron diseases (MND) can be categorized into amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) or progressive muscular atrophy (PMA). Although several studies have addressed the prevalence and incidence of ALS, there is a high heterogeneity in their results. Besides this, neither concept has been previously studied in PLS or PMA. Thus, the objective of this study was to estimate the prevalence and incidence of MND, (distinguishing ALS, PLS and PMA), in the Spanish regions of Catalonia and Valencia in the period 2011-2019. Two population-based Spanish cohorts were used, one from Catalonia and the other from Valencia. Given that the samples that comprised both cohorts were not random, i.e., leading to a selection bias, we used a two-part model in which both the individual and contextual observed and unobserved confounding variables are controlled for, along with the spatial and temporal dependence. The prevalence of MND was estimated to be between 3.990 and 6.334 per 100,000 inhabitants (ALS between 3.248 and 5.120; PMA between 0.065 and 0.634; and PLS between 0.046 and 1.896), and the incidence between 1.682 and 2.165 per 100,000 person-years for MND (ALS between 1.351 and 1.754; PMA between 0.225 and 0.628; and PLS between 0.409-0.544). Results were similar in the two regions and did not differ from those previously reported for ALS, suggesting that the proposed method is robust and that neither region presents differential risk or protective factors.

Identifiants

pubmed: 33737526
doi: 10.1038/s41598-021-85395-z
pii: 10.1038/s41598-021-85395-z
pmc: PMC7973725
doi:

Substances chimiques

Biomarkers 0
C9orf72 Protein 0
C9orf72 protein, human 0
SOD1 protein, human 0
Superoxide Dismutase-1 EC 1.15.1.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6207

Références

Lancet Neurol. 2016 Oct;15(11):1182-94
pubmed: 27647646
Neurology. 2001 Jan 23;56(2):239-44
pubmed: 11160962
Neuroepidemiology. 2018;51(3-4):149-157
pubmed: 30092573
J Public Health Med. 2003 Sep;25(3):254-7
pubmed: 14575204
Neurology. 2008 Feb 26;70(9):723-7
pubmed: 18299524
Neuroepidemiology. 2013;41(2):118-30
pubmed: 23860588
Hum Mutat. 2013 Jan;34(1):79-82
pubmed: 22936364
Neurology. 2010 Jun 8;74(23):1926; author reply 1926
pubmed: 20530332
Neurology. 2006 Mar 14;66(5):647-53
pubmed: 16534101
Surg Neurol Int. 2015 Nov 16;6:171
pubmed: 26629397
Int J Epidemiol. 2017 Feb 1;46(1):57-74
pubmed: 27185810
Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):278-83
pubmed: 23286747
Neurology. 1999 Feb;52(3):504-9
pubmed: 10025778
PLoS One. 2012;7(11):e48983
pubmed: 23155438
J Neurol Sci. 2006 Aug 15;247(1):21-8
pubmed: 16674979
Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):284-290
pubmed: 28152620
Can J Neurol Sci. 2007 Feb;34(1):69-73
pubmed: 17352350
Neurol Sci. 2016 Aug;37(8):1271-5
pubmed: 27098242
Curr Opin Neurol. 2019 Oct;32(5):771-776
pubmed: 31361627
MMWR Morb Mortal Wkly Rep. 2018 Nov 23;67(46):1285-1289
pubmed: 30462626
J Neurol. 2020 Apr;267(4):944-953
pubmed: 31797084
Neurol Int. 2015 Sep 24;7(2):5885
pubmed: 26487927
Comput Methods Programs Biomed. 2009 Mar;93(3):228-40
pubmed: 19059668
Gac Sanit. 2021 Mar-Apr;35(2):113-122
pubmed: 32014314
J Epidemiol. 2014;24(6):494-9
pubmed: 25373461
JAMA. 2014 Sep 17;312(11):1097-8
pubmed: 25057819
Neurol Clin. 2015 Nov;33(4):761-73
pubmed: 26515620
Neuroepidemiology. 2016;46(2):96-105
pubmed: 26731747
Eur J Neurol. 2009 Aug;16(8):920-4
pubmed: 19473365
Clin Neurophysiol. 2020 Aug;131(8):1975-1978
pubmed: 32387049
JAMA Neurol. 2021 Feb 1;78(2):165-176
pubmed: 33136137
J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):740-6
pubmed: 21402743

Auteurs

Maria A Barceló (MA)

Research Group On Statistics, Econometrics and Health (GRECS), University of Girona, Carrer de la Universitat de Girona 10, Campus de Montilivi, 17003, Girona, Spain. antonia.barcelo@udg.edu.
CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. antonia.barcelo@udg.edu.
Unidad Funcional de Motoneurona (UFMN), Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. antonia.barcelo@udg.edu.

Mònica Povedano (M)

Unidad Funcional de Motoneurona (UFMN), Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Juan F Vázquez-Costa (JF)

Unidad Funcional de Motoneurona (UFMN), Instituto de Investigación Sanitaria La Fe (IIS La Fe), Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Medicine Department, Facultad de Medicina, University of Valencia, Valencia, Spain.

Álvaro Franquet (Á)

Research Group On Statistics, Econometrics and Health (GRECS), University of Girona, Carrer de la Universitat de Girona 10, Campus de Montilivi, 17003, Girona, Spain.
CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Fundació Salut Empordà, Figueres, Spain.

Marta Solans (M)

Research Group On Statistics, Econometrics and Health (GRECS), University of Girona, Carrer de la Universitat de Girona 10, Campus de Montilivi, 17003, Girona, Spain.
CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Marc Saez (M)

Research Group On Statistics, Econometrics and Health (GRECS), University of Girona, Carrer de la Universitat de Girona 10, Campus de Montilivi, 17003, Girona, Spain.
CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH